Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination

Description

Some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. In a 6-session laboratory study, the investigators will be evaluating the effects of oxycodone and oxytocin (combined and separately, across sessions) on experimentally-induced pain, subjective effects, decision-making, and activation of different neural substrates.

Conditions

Pain

Talk to us

Study Overview

On this page

Study Details

Study overview

Some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. In a 6-session laboratory study, the investigators will be evaluating the effects of oxycodone and oxytocin (combined and separately, across sessions) on experimentally-induced pain, subjective effects, decision-making, and activation of different neural substrates.

Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination

Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination

Condition
Pain
Intervention / Treatment

-

Contacts and Locations

Gainesville

University of Florida, Gainesville, Florida, United States, 32611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Individuals fluent in English will participate.
  • * Must report recreational use of opioids.
  • * Be within 20% of their ideal body weight.
  • * Are not currently experiencing chronic pain (pain on most days during the past 3 months)
  • * Have a systolic blood pressure of \<=140 and diastolic blood pressure of \<= 90, and a heart rate \<= 90 beats per minute.
  • * Participants must also have a normal electrocardiogram (EKG) reading and bloodwork indicating no major health contraindications.
  • * Significant current physical disease or major psychiatric disorder.
  • * No self-reported current interest in drug abuse treatment.
  • * Women who are pregnant or nursing.
  • * Any comorbid illicit substance use disorders or current clinically significant withdrawal for any abused drug excluding nicotine and caffeine.
  • * Any conditions that preclude safety in the MRI scanner, such as: implanted electrical devices (e.g., cardiac pacemaker, neurostimulator); implanted metallic clips or pins (e.g., aneurysm clip); a history of working with metal (unless able to demonstrate participant is MRI safe), and claustrophobia.

Ages Eligible for Study

21 Years to 45 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Florida,

Meredith Berry, PhD, PRINCIPAL_INVESTIGATOR, University of Florida

Study Record Dates

2026-12-31